



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2023 #12

March 31, 2023

INSIDE:

Congressional Letters to FDA Supporting Shift to Individual Donor Assessment.....	2
BRIEFLY NOTED.....	3
March <i>Blood Bulletin</i> Published.....	4
Recording and Slides Available from Webinar on National Poll Findings on FDA's Proposed Individual Donor Assessment Change	4
Save the Date: ABC Summer Summit & MD Workshop	4
Participate in ABC's Blood Advocacy Week.....	5
RESEARCH IN BRIEF	6
MEMBER NEWS.....	6
GLOBAL NEWS	7
COMPANY NEWS	7
CALENDAR.....	9
POSITIONS.....	10

ABC Announces 2023 Advocacy Agenda

America's Blood Centers (ABC) in consultation with its Board of Directors, Policy Council, and input from member blood centers has published its [2023 Advocacy Agenda](#). The federal legislative and regulatory priorities that are most important to community blood centers are reflected within the ABC Advocacy Agenda which also includes clearly defined legislative and regulatory solutions that will guide the work of the association on behalf of its member blood centers. Through the 2023 Advocacy Agenda, ABC continues to urge the Administration, Congress, and industry stakeholders to promote the value of blood to patients, communities, and the healthcare system by:

- streamlining product licensure to allow blood centers to adapt to changing donor needs;
- expanding the pool of blood donors and available blood by funding local awareness efforts to recruit new and previously deferred donors made eligible by recent U.S. Food and Drug Administration (FDA) eligibility changes;
- ensuring blood transfusions are available to patients when and where they need blood;
- supporting a robust donor base by prioritizing blood donation as a national imperative;
- committing federal resources in support of the vital role of blood in the healthcare system; and
- reducing unnecessary and burdensome regulation to support innovation and blood product availability.

Additionally, ABC will take the priorities outlined in the 2023 ABC Advocacy Agenda to Congress during the upcoming [2023 Day on Capitol Hill](#) on April 26th. We encourage all members to take part in these virtual visits with members of Congress and their staff, capitalizing on the opportunity to educate Capitol Hill on the work you do daily to ensure a safe and available blood supply. [Registration](#) is open. ABC thanks its members and partners who have and continue to help advance the priorities and work of independent community blood centers. Please [contact](#) ABC Senior Director of Federal Government Affairs Diane Calmus, JD for questions or additional information. 💧

(Source: [MCN 23-029](#), 3/21/23)



Congressional Letters to FDA Supporting Shift to Individual Donor Assessment

Members of the [House](#) and [Senate](#) have submitted letters to the U.S. Food and Drug Administration (FDA) in support of shifting the current blood donor deferral policy for sexually active gay and bisexual men to an individual donor assessment. The Senate letter, led by Sen. Tammy Baldwin (D-Wis.) and 22 of her fellow senators, stated that proposed HIV guidance from the FDA “must also be effectively communicated to the public and implemented in a thoughtful manner. FDA must work closely with the nation’s blood collection establishments to ensure that they have the resources necessary to update their intake processes and adopt the new assessment tools. Blood collection establishments must also be educated and trained regarding these critical updates, and the agency must be cognizant of the need for gender inclusive language throughout. It is crucial that changes be closely monitored by the FDA, and that there be a structure in place for any necessary trouble-shooting as this policy is implemented.”

Additionally, the Senators encouraged the agency to work with “members of the LGBTQ+ community to effectively convey the importance of PrEP and the scientific basis for this deferral. It is essential that those currently taking PrEP continue to receive treatment, and we stand ready to support FDA’s efforts to track the latest data relevant to PrEP and blood donation.”

The House letter and efforts led by Reps. Mike Quigley (D-Ill.), Ritchie Torres (D-N.Y.), and Eric Sorensen (D-Ill.) and 23 of their colleagues commended the agency for the draft guidance and decision to use real-world data from the ADVANCE study to guide decision making. The coalition from the House stated that “While the framework for the deferral policy is a substantial improvement, we recognize that the draft guidance would still disproportionately prevent some members of the LGBTQI+ community, and especially [sexually active gay and bisexual men], from donating blood. We hope that continued analysis of the ADVANCE Study and further research will allow for updates to expand the opportunity for blood donation to more members of the LGBTQI+ community. We particularly hope that further analysis of the ADVANCE Study, new data, and improvements in testing and pathogen reduction technologies will support changes to the guidance’s current deferral for people taking preexposure prophylaxis, or PrEP.”

They closed the letter urging the FDA and other federal agencies to “continue to emphasize the integral role that PrEP plays in the effort to end the HIV epidemic, including throughout the implementation of this new guidance” and taking “the necessary steps to educate newly eligible donors, especially members of the LGBTQI+ community, about the new guidance and the importance of blood donation.”

(Sources: [Senate](#) and [House](#) Letters, 3/23/23 and 3/24/23) 💧

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2023 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America’s Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Jed Gorlin

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

memberservices@americasblood.org

America’s Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.



BRIEFLY NOTED

The General Court of the Commonwealth of Massachusetts has introduced bills in the [House](#) and [Senate](#) that would “increase access to blood donation.” Specifically, the legislation would amend current laws that restrict blood collection to hospitals, the Center for Blood Research, Inc. and the American Red Cross by opening up blood collection in the state to organizations “registered as a blood establishment” with the U.S. Food and Drug Administration.

(Sources: The General Court of the Commonwealth of Massachusetts [House](#) and [Senate](#) Bills, 2/16/23 and 3/30/23)

The Association for the Advancement of Blood & Biotherapies (AABB) has [announced](#) that it will resume unannounced assessments on May 12th. According to the notice, the organization will “implement the processes and procedures that were in place prior to the [public health emergency]. Assessors should not contact facilities to schedule assessment dates on or after May 12th.”

(Source: AABB [Announcement](#), 3/29/23) ♦

Upcoming ABC Webinars – Don’t Miss Out!

- **ABC Advocacy Forum** – April 4 from 2-3 PM EDT. A registration link and additional information available to ABC members [here](#).
- **ABC Blood Advocacy Week 2023** – April 24-28. [Registration](#) for events each day of the week as well as [ABC’s Day on Capitol Hill](#) (members-only) is open and the initial list of partners is now [available](#). More information available [here](#).
- Héma-Québec’s Perspective – Implementation Experience with Individual Donor Assessment – May 17 from 3-4 PM EDT. More information coming soon.





America's Blood Centers®
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

March Blood Bulletin Published

America's Blood Centers (ABC) has published the March 2023 edition of the *Blood Bulletin*. The issue titled "Directed Donations and COVID-19 mRNA Vaccinated Blood Donors" is available in [PDF](#) or [MS Word](#). The article was written by Daniela Hermelin, MD, Chief Medical Officer at ImpactLife; Louis Katz, MD, Chief Medical Officer Emeritus at ImpactLife; Nancy Van Buren, MD, Medical Director at Innovative Blood Resources and Community Blood Center of Kansas City, divisions of New York Blood Center; Kip Kuttner, DO, Vice President and Medical Director at Miller-Keystone Blood Center; Richard Gammon, MD, Medical Director at OneBlood; Debra Smith, MD, PhD, Medical Director at Carter BloodCare; and Kirsten Alcorn, MD, Co-Chief Medical Officer at Bloodworks Northwest. Contributors included: Rita Reik, MD, FCAP, Chief Medical Officer at OneBlood; Claudia S. Cohn, MD, PhD, Professor of Laboratory Medicine and Pathology at the University of Minnesota; and Theresa Nester, MD, Co-Chief Medical Officer at Bloodworks Northwest. *Blood Bulletin* is a quarterly publication reviewed and edited by ABC's Scientific, Medical, and Technical (SMT) Publications Committee.

(Source: [MCN 23-032](#), 3/30/23)

Recording and Slides Available from Webinar on National Poll Findings on FDA's Proposed Individual Donor Assessment Change

A recording and slides from the webinar "National Poll Findings on U.S. Food and Drug Administration's (FDA) Proposed Individual Donor Assessment Change" are available to ABC members on [CollABORate](#). The webinar presented polling data on national reactions to the FDA's proposed shift to an individual donor assessment. The findings are meant to help inform messaging, public resources, and the donor screening process as the blood community continues to communicate the reality of this change. This was the first such polling conducted in the U.S. and is only being released to ABC member blood centers and select other stakeholders. Information discussed on the webinar should be kept confidential within your blood center. If you have not received the full poll results and webinar slides, please contact ABC Director of Strategic Communications and National Partnerships [Jeff Gohringer](#).

Save the Date: ABC Summer Summit & MD Workshop

Mark your calendars for America's Blood Centers (ABC) [Summer Summit and Medical Directors Workshop](#) in St. Louis, Mo. The meeting will take place August 1st-3rd. Hotel [reservations](#) can be made now through the ABC block at Live! by Loews (St. Louis). Attendees will hear updates on blood center operational, scientific, and medical issues, case studies, engaging discussions, and have networking opportunities to connect with peers and colleagues. Additional details, including registration information and a preliminary agenda, are coming soon.

(continued on page 5)



INSIDE ABC (continued from page 4)

Participate in ABC's Blood Advocacy Week

ABC is hosting the inaugural [Blood Advocacy Week](#) April 24th-28th. This initiative reinforces ABC's commitment to advocacy and advancing policies that assist community blood centers. These virtual events aim to bring together members of the blood community, legislators, agency decision makers, advocates, providers, patients, and more to learn about and advance ABC's advocacy efforts on behalf of member blood centers. It includes the following:

- Monday, April 24th will be dedicated to discussing the current [status](#) of the nation's blood supply and trends impacting the collection and utilization of blood. Registration for the day's virtual event is [now open](#).
- Tuesday, April 25th will be dedicated to promoting the awareness of FDA donor [eligibility](#) changes impacting veterans and gay and bisexual men. Registration for the day's virtual event is [now open](#).
- Wednesday, April 26th will be ABC's virtual "Day on Capitol Hill." [Registration](#) is now open.
- Thursday, April 27th will be dedicated to examining changes that will expand early and increased access to blood, including in [pre-hospital](#) and [hospice](#) settings. Registration for the day's virtual event is [now open](#).
- Friday, April 28th will be dedicated to highlighting why increased [diversity](#) – racial, ethnic, and age – is important to patient care. Registration for the day's virtual event is [now open](#).

Additional updates will be provided in the coming weeks. ABC thanks Fresenius Kabi for being a Blood Advocacy Week sponsor. If you or your organization is interested in becoming an official [advocacy partner](#) or [sponsor](#), please contact [Jeff Gohringer](#), director of Strategic Communications and National Partnerships at ABC.

ABC also encourages all member blood centers to register for the [2023 "Day on Capitol Hill \(Virtual\)"](#) on April 26th. This "virtual" day provides an opportunity for member blood centers to connect with members of Congress and their staffs to discuss the ongoing work at the blood center and the work done collectively by ABC and community blood centers to advance the [ABC Advocacy Agenda](#). This event is a chance for individuals to let their voice be heard as ABC will arrange the virtual meetings for member blood centers with their members of Congress and provide additional resources to help inform them and their staff about the latest policies impacting the blood community. Take advantage of this opportunity to easily meet with your local Congressional leaders and build relationships.

Each person from the blood center who would like to participate in the "Day on Capitol Hill" must register individually. ABC will arrange for group meetings but will need information for each person in attendance. Please direct any questions to ABC Senior Director of Federal Government Affairs [Diane Calmus, JD](#).

(Source: [MCN 23-020](#), 2/24/23) ♦





RESEARCH IN BRIEF

Efficacy and Safety of 4-Factor PCC in Massive Transfusion. A multisite [trial](#) in the *Journal of the American Medical Association* was conducted to “test the hypothesis that systematic 4-factor prothrombin complex concentrate (4F-PCC) administration combined with a ratio based transfusion protocol is superior to ratio-based transfusion alone in reducing 24-hour total blood product consumption in patients at risk of massive transfusion.” The researchers explained that the “randomized, placebo-controlled clinical trial took place in 12 level I trauma centers in France. Trial recruitment lasted from December 2017 to August 2021...All adult patients (≥ 18 years of age) with trauma directly admitted from the injury scene to one of the participating centers were considered for potential enrollment.” A trained nurse “prepared either 4F-PCC or placebo.” The authors noted that “[t]he active intervention was 4F-PCC at a dose of 25 IU of factor IX per kg (1 mL/kg). The placebo was 1 mL/kg of 0.9 percent saline solution...On admission, patients in both groups were treated with a packed red blood cell concentrate (PRBC): fresh frozen plasma (FFP) ratio between 1:1 and 2:1.” The trial’s stated “primary outcome was the total number of all blood product units consumed within the first 24 hours after arrival...[A]rterial or venous thromboembolic events were a secondary outcome.” A total of 324 patients were analyzed and “a total of 308 received the study intervention (4F-PCC or placebo) within the first hour of admission (159 in the 4F-PCC group and 149 in the placebo group).” Of these “233 (73 percent) were men and the median age was 39 (26.5-56) years, median Injury Severity Score was 36 (26-50)...The number of patients with at least one thromboembolic event was greater among those who received 4F-PCC vs. placebo (56 [35 percent] vs 37 [24 percent]; absolute difference, 11 percent [95 percent CI, 1-21 percent]; relative risk, 1.48 [95 percent CI, 1.04-2.10]; $P = .03$.” The authors concluded that “[t]his randomized, double-blind clinical trial found no beneficial effect of adding 4F-PCC to a ratio-based transfusion strategy in patients with severe trauma at risk of massive transfusion, and possible harm from a higher rate of thromboembolic events...The findings do not support systematic 4F-PCC use in patients with trauma at risk of massive transfusion.”

Citation: Bouzat, P., Charbit, J., Abback, P., *et al.* [Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial.](#) *JAMA.* 2023.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧

MEMBER NEWS



Carter BloodCare President and Chief Executive Officer (CEO) Dr. Merlyn Sayers with honoree and Carter BloodCare Medical Director Emeritus Dr. Margie B. Peschel.

Carter BloodCare held a dedication ceremony in Fort Worth, Texas, renaming its Rosedale Donor Center in honor of Margie B. Peschel, MD. Joined by family, friends and health care colleagues on March 29th, Dr. Peschel, Medical Director Emeritus with Carter BloodCare, was recognized for her outstanding commitment to the North Texas community and Carter BloodCare’s mission to save lives by making transfusion possible. Throughout her decades-long career, Dr. Peschel served as a valued, trusted mentor for medical professionals and was instrumental in significantly advancing the role and reach of blood banking to help an increasing number of patients in need. Said one colleague, “The impact Dr. Peschel has had on blood donation and the medical community is without comparison. She is an inspiration.”

(Source: Carter BloodCare Announcement, 3/30/23)

Contributed by James Black, Senior Public Relations Specialist at Carter BloodCare

(continued on page 7)



MEMBER NEWS (continued from page 6)

The Blood Connection will partner with MUSC Health Orangeburg beginning April 1st. According to an announcement from The Blood Connection, the organization “will assume all blood collection operations in the area to provide blood products for MUSC Health Orangeburg patients.” Delisa English, president and CEO, added in the announcement “[w]e are honored to partner with MUSC Health Orangeburg to continue the strong legacy of blood services in this community. MUSC Health and The Blood Connection have very similar missions, and we believe that this partnership will be a tremendous, long-term asset for MUSC Health Orangeburg patients and this community. We are eager to work with the many schools, employers, churches, and others who have held drives and contributed blood products through MUSC Health Orangeburg’s donor center and bloodmobiles.”

(Source: The Blood Connection Announcement, 3/30/23) 💧

GLOBAL NEWS

The World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) updated its guidance this week regarding additional booster doses of approved COVID-19 vaccines. The guidance bases recommendations by classifying individuals into high, medium, or low priority-use groups. At this time, the SAGE advised individuals in the high priority-use to get “an additional booster of either six or 12 months after the last dose, with the timeframe depending on factors such as age and immunocompromising conditions. All the COVID-19 vaccine recommendations are time-limited, applying for the current epidemiological scenario only, and so the additional booster recommendations should not be seen as for continued annual COVID-19 vaccine boosters.” Additionally, the SAGE recommended that nations “can consider using BA.5 bivalent mRNA vaccine for the primary series.”

(Source: WHO [News Release](#), 3/28/23)

Zipline recently announced that it has performed “a successful test flight of its medical logistics drones” in Kisumu County, Kenya. The company plans to use its drone network to provide blood products and medical supplies throughout the area’s 400 healthcare facilities. Zipline also currently uses drones to access remote parts Côte d’Ivoire and Nigeria, providing those country’s blood products and medical supplies as well.

(Source: *Air Med & Rescue*, [Zipline conducts Kisumu test flight](#), 2/6/23) 💧

COMPANY NEWS

Researchers from **Cerus Corp.** have [published](#) findings in *Transfusion* that report on national hemovigilance data in France “evaluat[ing] platelet component safety and utilization” two years before and three years after the national adoption of pathogen reduction (PR) technology for platelets. The study titled “Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7-day storage” found that no transfusion-transmitted bacterial infections “were associated with” PR platelets. “Hepatitis E (HEV) a non-enveloped virus resistant to PR, were reported” during the study period.

Citation: Pitman, J., Payrat, J-M., Park, M-S., *et al.* “[Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7-day storage.](#)” *Transfusion*. 2023.

(continued on page 8)



COMPANY NEWS (continued from page 7)

QuidelOrtho has created a “[Learning Hub](#)” that contains educational resources and content describing advancements in science and technology. The hub contains podcasts on topics including key learnings from rare blood programs, how blood groups are discovered, and resolving antibodies to high-prevalence antigens. It also contains a white paper on preparedness for blood services for emerging infectious diseases that could impact the blood supply.

(Source: QuidelOrtho Announcement, 1/18/23) ♦

National Institutes of Health (NIH) Department of Transfusion Medicine Specialist in Blood Bank Training Program

NIH is looking for individuals [interested](#) in its Blood Bank Training [Program](#). Find more information available below!

Specialist in Blood Bank Technology Transfusion Medicine Program at the NIH Clinical Center

Accredited by:

The Commission on Accreditation of Allied Health Education Programs

ASCP SBB Certification: graduates 2017-2022

Pass rate = 90%

Recent awards and publications:

- AABB Future Leader Scholarship Award (2016, 2017, 2019), Top SBB Student Poster (2016)
- Remley VA, Collins A, Underwood S, Jin J, Kim Y, Cai Y, Prochazkova M, Moses L, Byrne KM, Jin P, Stroncek DF, Highfill SF. Optimizing a Fully Automated and Closed System Process for Red Blood Cell Reduction of Human Bone Marrow Products. *Cytotherapy* 2023 Jan 27;S1463-249(22)
- Byrne KM, Collins AA, Seifu R, Paige TD, Flegel WA. Using social media to recruit for a face-to-face Specialist in Blood Bank (SBB) Technology program. *Immunohematology* 2022;38:62-63.
- Tynuv M, Flegel WA. Quality improvement with platelet additive solution for safer out-of-group platelet transfusions. *Immunohematology* 2019 Sep;35(3):108-115
- Byrne KM, Mercado CMC, Nnabue TNJ, Paige TD, Flegel WA. Inhibition of blood group antibodies by soluble substances. *Immunohematology* 2019;35:102
- Lodermeier MA, Byrne KM, Flegel WA. Red blood cell sedimentation of Apheresis Granulocytes. *Transfusion* 2017;57:2551-2552

Students are employees working in the Transfusion Service Laboratory.

Program Website



The program does not have any associated costs!!!

For more information, please contact us via email or visit our website:

CC-DTMSBBApplication@mail.nih.gov

<https://www.cc.nih.gov/dtm/research/sbb.html>





CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

2023

April 4. **ABC Advocacy Forum (Virtual)**. More information available [here](#).

April 12-13. **Centers for Disease Control and Prevention (CDC) Clinical Laboratory Improvement Advisory Committee Meeting (Virtual)**. More information available [here](#).

April 20. **End of Selection Criteria Based on Sexual Orientation – International Symposium on Alternatives to Donation Deferral (Virtual)**. [Registration](#) is open. More information available [here](#).

April 24-28. **ABC Blood Advocacy Week (Virtual)**. More information available [here](#).

April 25. **U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products (OTP) Town Hall: Gene Therapy Chemistry, Manufacturing, and Controls – April 2023 (Virtual)**. [Registration](#) is open. More information available [here](#).

April 26. **ABC Day on Capitol Hill (Virtual)**. [Registration](#) is open. More information available [here](#).

April 26. **FDA Blood Products Advisory Committee (BPAC) Meeting (Virtual)**. More information available [here](#).

April 27. **FDA's CBER Office of Tissues and Advanced Therapies (OTAT) Public Listening Meeting: Methods and Approaches for Capturing Post-Approval Safety and Efficacy Data on Cell and Gene Therapy Products (Virtual)**. [Registration](#) is open. More information available [here](#).

May 4. **The National Biodefense Science Board, managed and operated by the Administration for Strategic Preparedness and Response, Public Meeting (Virtual)**. [Registration](#) is open. More information available [here](#).

May 9-11. **2023 ADRP Conference, Charlotte, N.C.** [Registration](#) is open. Additional information is available [here](#).

May 10-11. **29th IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Bologna, Italy**. More information available [here](#).

May 17. **Héma-Québec's Perspective – Implementation Experience with Individual Donor Assessment**. More information coming soon.

Aug. 1-3. **ABC Medical Directors Workshop and Summer Summit, St. Louis, Mo.** More information available [here](#).

Sept. 17-20. **American Association of Tissue Banks Annual Meeting, National Harbor, Md.** More information available [here](#).

Sept. 20-21. **2023 ADRP Master Class (Virtual)**. More information coming soon.

Oct. 9-11. **Advanced Medical Technology Association (AdvaMed) The MedTech Conference, Anaheim, Calif.** More information available [here](#).

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** More information available [here](#). 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Enterprise Medical Director. This position is part of an enterprise-wide Chief Medical Office. This role is responsible for providing medical directorship, administrative, technical, and clinical operations of the assigned hospitals, systems, program, and services as well as support medical directorship of New York Blood Center (NYBC) or the greater NYBC enterprise. This position supports management in making information medical decisions, develops and reviews medical oversight and responsibility for the technical and medical policies, processes, and procedures of specific operations. New York Blood Center Enterprises (NYBCe) is one of the largest community-based, non-profit blood collection and distribution organizations in the United States. We proudly serve as a vital community lifeline dedicated to serving patients and advancing global public health. Our four-part mission is to provide high quality blood products, therapeutic apheresis, cord, and stem cell services, conduct innovative research, develop new products and technologies, and train the next generation of industry leaders. We serve more than 600 hospitals through our six east coast and mid-west divisions and work with dozens of research organizations, academic institutions, and biopharmaceutical companies through our five research enterprises. Click here to view the full job description and apply: [Enterprise Medical Director in New York, New York](#)

Transfusion Lab Supervisor. Join Florida's leading blood bank, **OneBlood**, as a Lab Supervisor, working 2nd shift, in Lakeland, FL. Bring your leadership, technical expertise, and management experience to support the transfusion testing procedures on patient and/or donor samples. Qualified candidates should possess three (3) or more years' experience in a clinical laboratory, preferably blood banking environment, including one (1) or more years' experience in supervision and management experience, as well as a valid and current Florida Clinical Laboratory Technologist license in Immunohematology or Blood Banking; Supervisor license strongly preferred. To apply and view a complete Job Description of this position, visit www.oneblood.org/careers. OneBlood, Inc. is an Equal Opportunity Employer/Vet/Disability.

Registered Nurse. If you have a passion to join a team that is providing specialized and focused, cutting-edge therapeutic apheresis procedures in a one-on-one patient care environment, consider joining OneBlood as a **Registered Nurse**. **OneBlood**, a proven leader in blood banking, also needs dedicated nurses to join our organization to provide their exceptional nursing skills to the hospital's we support and their patient care needs. This position includes a competitive benefit package, 403(b) retirement plan with company contribution PLUS a company match, paid time off, cell phone stipend, mileage reimbursement, tuition assistance, professional growth and much more. This position will be based out of the St.

Petersburg/Tampa area, close to some of the most gorgeous beaches in the nation! If you want to join our life saving mission and team of dedicated employees, visit our **Careers** page at www.oneblood.org to learn more. OneBlood, Inc. is an Equal Opportunity Employer/Vet/Disability.

Medical Technologists Needed with experience working in a Molecular Lab! OneBlood is currently recruiting for Medical Technologists to work in our Reference Lab in St. Petersburg, Florida. This position will perform basic through advanced testing serologic and molecular (ex: HEA, HLA, RHD, RHCE, NGS) procedures on patient and/or donor samples and interpret results in accordance with regulatory guidelines and organizational policies and procedures. Applicants must have a bachelor's degree in a biological science or related scientific field from an accredited college or university or an equivalent combination of education, certification, training and/or experience. Applicants must also have a valid and current Florida Clinical Laboratory Technologist license, or eligible, in Immunohematology or Blood Banking. To apply and view a complete Job Description of these positions, go to www.oneblood.org and click on the **Careers** tab. OneBlood, Inc. is an Equal Opportunity Employer/Vet/Disability

Manager of Donor Resources. The Blood Connection is seeking a Manager of Donor Resources in Asheville, NC, Raleigh, NC, and Greenville, SC to provide oversight to our recruitment teams within these divisions. This position directs Account Managers and Business Development Representatives to strategically manage our existing portfolio of blood donor groups and new business to reach collection targets. The Manager of Donor Resources monitors progress to goal proactively and effectively coaches and manages the team to success. The ideal candidate will have a strong background in territory management and team building. Candidates must possess excellent interpersonal, analytical, and strategic planning abilities. We offer an exceptional benefits package including a generous 401k match, 30 days PTO, company bonuses, tuition reimbursement, cell phone stipend, and yearly increases. Join one of the fastest growing blood centers in the country and help make an impact in your community today! How to apply: [Manager of Donor Resources](#)

Regional Manager. LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management experience and a passion for making a difference. The Regional Manager for McDonough, Ga. is responsible for overseeing daily operations of the region, is organized and decisive, and can motivate the team to reach daily and long-range collection goals. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit

(continued on page 11)



POSITIONS (continued from page 10)

our careers page to learn more about this position and to apply. <https://www.lifesouth.org/work-at-lifesouth/> 💧